Quantum Biopharma LTD Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
AdvisorShares Trust has reported beneficial ownership of 203,564 Class B Subordinate Voting Shares in Quantum Biopharma Ltd., representing 5.33% of the class.
NASDAQ
Malone Wealth Ventures LLC has reported a 9.8% beneficial ownership stake in Quantum Biopharma Ltd., holding 375,752 shares of common stock.
NASDAQ
Malone Wealth Ventures LLC has reported a 27.4% beneficial ownership stake in Quantum Biopharma Ltd.'s common stock.
NASDAQ
Malone Wealth Ventures LLC has filed an amended Schedule 13G, reporting a beneficial ownership of 21.8% of Quantum Biopharma Ltd.'s common stock.
NASDAQ
Malone Wealth Ventures LLC has disclosed a beneficial ownership of 19.4% of Quantum Biopharma Ltd.'s common stock, holding 735,148 shares as a passive investment.
NASDAQ
Malone Wealth Ventures LLC has disclosed a 19.4% beneficial ownership stake in Quantum Biopharma Ltd., holding 735,148 shares of common stock.
NASDAQ
Malone Wealth Ventures LLC has filed an amended Schedule 13G, reporting a 19.4% beneficial ownership stake in Quantum Biopharma Ltd.'s common stock as of July 10, 2025.
NASDAQ
Malone Wealth Ventures LLC has filed an amended Schedule 13G, disclosing a 19.9% beneficial ownership stake in Quantum Biopharma Ltd.
NASDAQ
Malone Wealth Ventures LLC has filed a Schedule 13G, reporting a beneficial ownership of 13.2% of Quantum Biopharma Ltd.'s common stock.